WHO’s Technical Advisory Group sought additional clarifications from Bharat Biotech
The World Health Organization (WHO) has sought additional clarifications to decide on much-awaited Emergency Use Listing (EUL) to the Bharat Biotech’s COVID-19 vaccine, Covaxin.
Before giving a nod for Emergency Use Listing (EUL) of the Covaxin, the Technical Advisory Group of WHO has sought additional data from vaccine manufacturer Bharat Biotech.
“Final risk-benefit assessment” to be conducted by the WHO’s Technical Advisory Group after receiving additional data from the manufacturer.
Hyderabad-based Bharat Biotech is expected to submit the data by this weekend. The Technical Advisory Group may meet for the final risk-benefit assessment on November 3. The company also submitted additional info at WHO’s request on September 27.
The Technical Advisory Group for Emergency Use Listing (TAG-EUL) provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.
Earlier, Bharat Biotech had responded to all clarifications sought by the WHO on their EUL Application for the Made in India COVID-19 vaccine — Covaxin.
The pharma firm, popularly known for vaccine manufacturing, said it has regularly provided the global health watchdog with all the details and was awaiting EUL approval.
[With Inputs from IANS]
PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views
For all the latest updates, download PGurus App.
